Regentis BiomaterialsRGNT -1.19%14 Piotroski F-Score is 4 as of Jun. 25, 2026, which is at its 10-year median of 4.00. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Regentis Biomaterials ranks worse than 56.27% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Regentis Biomaterials has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Regentis Biomaterials's Piotroski F-Score or its related term are showing as below:
RGNT'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 4
Current: 4
During the past 6 years, the highest Piotroski F-Score of Regentis Biomaterials was 4. The lowest was 2. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Regentis Biomaterials Piotroski F-Score Related Terms
Regentis Biomaterials Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Regentis Biomaterials's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGNT vs MHUAF, LUCY, CUPR: Piotroski F-Score Comparison
For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regentis Biomaterials Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Regentis Biomaterials's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Regentis Biomaterials's current Net Income (TTM) was -13.65.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Regentis Biomaterials's current Cash Flow from Operations (TTM) was -1.38.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Regentis Biomaterials's return on assets of this year was -28.3153527. Regentis Biomaterials's return on assets of last year was 13.33611111.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Regentis Biomaterials's gearing of this year was 0. Regentis Biomaterials's gearing of last year was 0.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Regentis Biomaterials's current ratio of this year was 2.6506611. Regentis Biomaterials's current ratio of last year was 0.074291.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Regentis Biomaterials's number of shares in issue this year was 0.567. Regentis Biomaterials's number of shares in issue last year was 5.179.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Regentis Biomaterials's gross margin of this year was . Regentis Biomaterials's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Regentis Biomaterials's asset turnover of this year was 0. Regentis Biomaterials's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
1
+
1
+
0
+
0
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Regentis Biomaterials has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Regentis Biomaterials (RGNT) has a Piotroski F-Score of 4 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Regentis Biomaterials and its competitors. This is near median its historical median of 4.00. Over the past decade, Regentis Biomaterials' Piotroski F-Score has ranged from 2.00 to 4.00. According to the industry distribution chart, Regentis Biomaterials ranks #453 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 56.3%.
Is Regentis Biomaterials' Piotroski F-Score too high?
Regentis Biomaterials' current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 4.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Regentis Biomaterials' value of 4 is 20% below this industry median. Based on the distribution chart, Regentis Biomaterials ranks #453 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' Piotroski F-Score compare to MHUAF and LUCY?
According to the Medical Devices & Instruments industry distribution chart, Regentis Biomaterials ranks #453 out of 805 companies for Piotroski F-Score. This places Regentis Biomaterials in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Regentis Biomaterials' value of 4 is 20% below this benchmark. Historically, Regentis Biomaterials' own Piotroski F-Score has ranged from 2.00 to 4.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Regentis Biomaterials has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regentis Biomaterials's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Regentis Biomaterials and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regentis Biomaterials's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Medical Devices & Instruments industry median of 5.00. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current Piotroski F-Score is 4 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score
Get the complete analysis for RGNT
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGNT has been successfully added to your 
